8-K - Xtant Medical Holdings, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Xtant Medical Holdings, Inc. reported Q4 and full-year 2025 financial results with revenue of $32.4M and $134.0M respectively, achieving net income of $5.0M and adjusted EBITDA of $16.3M, alongside divestiture proceeds and 2026 revenue guidance of $95-99M.

Key Takeaways

1Full-year 2025 revenue $134.0 million, up 14% from $117.3 million in 2024.

2Full-year 2025 net income $5.0 million or $0.03 per diluted share vs net loss $16.5 million in 2024.

3Non-GAAP adjusted EBITDA $16.3 million for full-year 2025 vs loss of $2.3 million in 2024.

4Q4 2025 revenue $32.4 million, up 3% from $31.5 million, impacted by $2.0 million from Companion Spine divestiture.

5Sold non-core Coflex/CoFix assets and international hardware to Companion Spine for $21.4 million cash.

62026 revenue guidance $95-99 million; cash position over $22 million post-divestiture payment, term loan $11.2 million.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Financial Results

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release of Xtant Medical Holdings,

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1